Birkásová M, Birkás O, Flynn M J, Cort J H
Pediatrics. 1978 Dec;62(6):970-4.
Desmopressin (1-desamino-[8-D-Arg]-vasopressin) (DDAVP) was given by nose drops to 22 children with persistent nocturnal enuresis (mean age, 6.6 +/- 2.9 years; range, 4 to 12 years) the evening before sleep. With saline alone as placebo and with comparison to enuretic frequency before the onset of the trial, fortnightly periods were compared under double-blind conditions with the children at home. Pretreatment and placebo fortnights showed wetting frequencies (nights per fortnight) of 10.6 +/- 4.9 and 11.0 +/- 4.4, respectively. The value of the fortnight during desmopressin therapy was 4.2 +/- 4.5, which was significantly different from either of the previous means (P less than .01). Of the 22 subjects, four failed to react to therapy at all. There was decreased enuretic frequency in the remaining 18, of whom 12 decreased markedly or ceased wetting. One month after the trial, seven of the respondents were dry with desmopressin therapy. There was clear evidence of a large nocturnal volume of dilute urine before treatment in six of the respondents in whom such measurements could be reliably made. These children responded to dehydration with urine concentration, however, so that the suggestion can be made that a failure to develop a normal diurnal pattern of urine volume and concentration may underly some cases of enuresis.
去氨加压素（1-去氨基-[8-D-精氨酸]-血管加压素）（DDAVP）在睡前当晚以滴鼻剂形式给予22名持续性夜间遗尿症儿童（平均年龄6.6±2.9岁；范围4至12岁）。以生理盐水单独作为安慰剂，并与试验开始前的遗尿频率进行比较，在双盲条件下，让孩子们在家中对每两周的时间段进行比较。治疗前和安慰剂组每两周的尿床频率（每两周的夜晚数）分别为10.6±4.9和11.0±4.4。去氨加压素治疗期间每两周的值为4.2±4.5，与之前的任何一个平均值均有显著差异（P＜0.01）。22名受试者中，有4名对治疗完全无反应。其余18名遗尿频率降低，其中12名显著降低或停止尿床。试验后一个月，7名有反应者在去氨加压素治疗下不再尿床。在6名能够可靠进行此类测量的有反应者中，有明确证据表明治疗前夜间尿量多且尿液稀释。然而，这些儿童对脱水有尿液浓缩反应，因此可以认为未能形成正常的昼夜尿量和浓度模式可能是某些遗尿症病例的潜在原因。
